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Abstract
Currently, two neuraminidase (NA) inhibitors, oseltamivir and zanamivir, which must be administrated twice daily for 5 days
for maximum therapeutic effect, are licensed for the treatment of influenza. However, oseltamivir-resistant mutants of
seasonal H1N1 and highly pathogenic H5N1 avian influenza A viruses have emerged. Therefore, alternative antiviral agents
are needed. Recently, a new neuraminidase inhibitor, R-125489, and its prodrug, CS-8958, have been developed. CS-8958
functions as a long-acting NA inhibitor in vivo (mice) and is efficacious against seasonal influenza strains following a single
intranasal dose. Here, we tested the efficacy of this compound against H5N1 influenza viruses, which have spread across
several continents and caused epidemics with high morbidity and mortality. We demonstrated that R-125489 interferes with
the NA activity of H5N1 viruses, including oseltamivir-resistant and different clade strains. A single dose of CS-8958
(1,500 mg/kg) given to mice 2 h post-infection with H5N1 influenza viruses produced a higher survival rate than did
continuous five-day administration of oseltamivir (50 mg/kg twice daily). Virus titers in lungs and brain were substantially
lower in infected mice treated with a single dose of CS-8958 than in those treated with the five-day course of oseltamivir.
CS-8958 was also highly efficacious against highly pathogenic H5N1 influenza virus and oseltamivir-resistant variants. A
single dose of CS-8958 given seven days prior to virus infection also protected mice against H5N1 virus lethal infection. To
evaluate the improved efficacy of CS-8958 over oseltamivir, the binding stability of R-125489 to various subtypes of
influenza virus was assessed and compared with that of other NA inhibitors. We found that R-125489 bound to NA more
tightly than did any other NA inhibitor tested. Our results indicate that CS-8958 is highly effective for the treatment and
prophylaxis of infection with H5N1 influenza viruses, including oseltamivir-resistant mutants.
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Introduction
Human H1N1 and H3N2 influenza A viruses are highly
contagious and cause ‘‘seasonal influenza’’ worldwide. The global
impact of influenza epidemics is estimated to be 3.5 million cases
of severe illness and 300,000 to 500,000 deaths annually [1]. The
elderly, young children, and immunocompromised patients are
particularly at risk, with substantial morbidity and mortality
among these groups [2]. In addition, the emergence of a virus
possessing hemagglutinin and neuraminidase (NA) to which
humans have limited immunological memory creates the potential
for ‘‘pandemic influenza’’. In 1997, human infections with highly
pathogenic H5N1 avian influenza viruses were first documented in
Hong Kong [3–5]. Since then, these viruses have spread
throughout Asia, Europe, and Africa with high morbidity and
mortality among avian species and with occasional transmission to
humans with high mortality (http://www.who.int/csr/disease/
avian_influenza/en/). Although human-to-human transmission is
rare, once the H5N1 viruses acquire this ability, a devastating
pandemic may be inevitable.
Two countermeasures are available to control human influenza:
vaccination and antiviral treatment. Although vaccination plays a
critical role in influenza prophylaxis, it takes more than six months
to produce sufficient vaccine to cover a large proportion of the
human population upon the emergence of a new strain [6].
Therefore, antivirals are important tool to mitigate an influenza
pandemic.
Currently, two types of anti-influenza drug are available: M2
ion channel blockers (amino-adamantines; amantadine and
rimantadine) [7] and NA inhibitors (oseltamivir and zanamivir)
PLoS Pathogens | www.plospathogens.org 1 February 2010 | Volume 6 | Issue 2 | e1000786[8]. However, amino-adamantine-resistant viruses readily emerge
and are already prevalent worldwide among the seasonal influenza
viruses (both H1N1 and H3N2 subtypes [9,10]). In fact, the
recently emerged swine-origin pandemic (H1N1) 2009 virus is
already amino-adamantine-resistant [11]. Moreover, the emer-
gence of amino-amantadine-resistant H5N1 viruses in Vietnam,
Cambodia, and Thailand [12] has prompted the World Health
Organization to recommend oseltamivir for the treatment and
prophylaxis of human H5N1 influenza virus infections [13].
Accordingly, many countries have stockpiled oseltamivir in
anticipation of an H5N1 pandemic.
NA inhibitor-resistant viruses were thought to not readily
emerge, yet studies have demonstrated a higher prevalence of
oseltamivir-resistant viruses than was expected among oseltamivir-
treated patients [14,15]. Person-to-person transmission of oselta-
mivir-resistant influenza B virus has been reported [16].
Moreover, oseltamivir-resistant H1N1 viruses were isolated in
Europe during the 2007–2008 season [17] and are now widely
circulating [18] (http://www.who.int/csr/disease/influenza/
h1n1_table/en/index.html). Oseltamivir-resistant H5N1 viruses
have been isolated from patients in Vietnam and Egypt [19,20]
(http://www.emro.who.int/csr/media/pdf/ai_press_22_01_07.
pdf), some of whom died despite early initiation of drug
treatment, suggesting that the resistant variants are just as
virulent as their sensitive counterparts. These epidemics of
oseltamivir-resistant influenza viruses, therefore, necessitate the
development of alternative antiviral agents.
In response to the need for new anti-influenza drugs, CS-8958,
a prodrug of the novel neuraminidase inhibitor R-125489, has
been developed [21]. R-125489 inhibits the NA activity of various
influenza A and B viruses in vitro, including N1-N9 subtypes and
oseltamivir-resistant viruses, with limited cytotoxicity [21]. Fur-
ther, a single dose of CS-8958 prolonged the survival of mice
infected with a mouse-adapted A/Puerto Rico/8/34 (H1N1) [21].
Recently, we demonstrated the therapeutic efficacy of CS-8958 in
mice infected with the swine-origin pandemic (H1N1) 2009 virus
[22]. However, its efficacy against H5N1 influenza viruses, whose
pathogenicity is substantially higher than that of seasonal mouse-
adapted human influenza and swine-origin pandemic (H1N1)
2009 viruses [23], has not been assessed in vivo.
Here, we examined the efficacy of CS-8958 against H5N1
influenza viruses in vitro and in vivo. The binding stability of R-
125489 to H1N1, H3N2, and type B influenza viruses was also
assessed. We demonstrate the potential of CS-8958 as an
alternative antiviral against influenza viruses, including oseltami-
vir-resistant mutants.
Methods
Viruses and cells
H5N1 influenza viruses A/Hanoi/30408/05 clone7 (HN-
30408cl7;; oseltamivir-sensitive) and clone9 and clone3 (oseltami-
vir-resistant) possessing a histidine-to-tyrosine substitution at
position 274 (H274Y) and an asparagine-to-serine substitution at
position 294 (N294S) in NA, respectively [20], and A/Indonesia/
UT3006/05 (Ind3006) were isolated in Madin-Darby canine
kidney (MDCK) cells. A/Vietnam/1203/04 (H5N1; VN1203) was
generated in 293T cells by reverse genetics as described below.
HN30408 and VN1203 are categorized as clade 1 viruses [24],
whereas Ind3006 is in clade 2.1.3 [25]. Influenza viruses A/New
Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/
Mie/1/93 were provided by the National Institute of Infectious
Diseases, Japan. MDCK and 293T cells were maintained in
Eagle’s minimal essential medium (MEM) supplemented with 5%
newborn calf serum (Sigma, St. Louis, MO) and in Dulbecco’s
modified Eagle’s medium (Sigma) supplemented with 10% fetal
calf serum, respectively. Both cell lines were cultured at 37uCi n
5% CO2. All experiments with H5N1 viruses were performed in a
biosafety level 3 containment laboratory inspected by the Ministry
of Agriculture, Forestry and Fisheries, Japan.
Compounds
CS-8958, R-125489 (the active metabolite of CS-8958),
zanamivir and peramivir were synthesized according to published
procedures [26–28]. Oseltamivir carboxylate (the active metabo-
lite of oseltamivir phosphate) was prepared from oseltamivir
phosphate extracted from TamifluH (Roche Laboratories Inc.,
Basel, Switzerland).
Reverse genetics
Plasmids for the expression of VN1203 viral RNAs were
constructed as described previously [29]. The H274Y and N294S
mutations were independently introduced into the plasmid for the
VN1203 NA gene. Wild-type and oseltamivir-resistant VN1203
(VN1203-H274Y and VN1203-N294S) were also generated by
reverse genetics, as described previously [30], propagated in
MDCK cells twice, and stored at 280uC as stock viruses. All
constructed plasmids were sequenced to ensure the absence of
unwanted mutations.
NA activity inhibition assay
NA sensitivity to the NA inhibitors was evaluated by using an
NA activity inhibition assay based on the method of Gubareva
et al [31]. Methylumbelliferyl-N-acetylneuraminic acid (MU-
NANA, Sigma), at a final concentration of 0.1 mM, was used as
the fluorescent substrate. Diluted virus containing 800 to 1200
fluorescence units of MUNANA was mixed with the test
compound (0.01 nM-1 mM) in 33 mM 2-[N-morpholino]ethane-
sulfonic acid (pH 6.0) containing 4 mM CaCl2 and incubated for
30 min at 37uC. After adding the substrate and incubating at 37uC
for 1 h, the reaction was stopped by adding 0.1M NaOH in 80%
ethanol (pH 10.0). Fluorescence was measured at an excitation
wavelength of 360 nm and an emission wavelength of 465 nm.
The relationship between the concentration of inhibitor and the
percentage of fluorescence inhibition was determined and 50%
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influenza patients infected with H5N1 or other subtype
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lating those findings.
Therapeutic efficacy of NA inhibitors in mice
Six-week-old female BALB/c mice (Japan SLC Inc., Shizuoka,
Japan) were anesthetized by sevoflurane inhalation and intrana-
sally infected with 4 MLD50 (50% mouse lethal dose) of viruses in
50 ml of phosphate-buffered saline (PBS). Eight or ten mice per
group were given CS-8958 (75, 750, or 1,500 mg/kg) 2 h post-
infection (pi) intranasally or oseltamivir phosphate (5 or 50 mg/kg
twice a day for 5 days or 10 or 100 mg/kg once 2 h pi) orally.
Control mice for the CS-8958 and oseltamivir phosphate groups
received saline intranasally and water orally, respectively. Mouse
survival was monitored daily for 21 days after virus infection.
On days 3 and 6 pi, three mice per group were euthanized for
virologic examinations. To determine the virus titers in lungs and
brain, each organ was homogenized in PBS containing antibiotics.
Cellular debris was removed by centrifugation at 3,0006g for
10 min, after which the supernatants were subjected to plaque
assays in MDCK cells.
Prophylactic efficacy of NA inhibitors in mice
Eight BALB/c mice per group were given CS-8958 (75, 750, or
1,500 &g/kg) intranasally or oseltamivir phosphate (10 or
100 mg/kg) orally 7, 3, or 1 day before or 2 h after infection
with 4 MLD50 of HN30408cl7. Mouse survival was monitored
daily for 21 days after virus infection. As above (except for the
10 mg/kg oseltamivir phosphate), we also determined the virus
titers in the lungs and brain of three mice per group on days 3 and
6 pi.
Binding stability of NA inhibitors
To assess the binding stability of NA inhibitors to viral NAs, we
measured the NA activity of viruses treated with excess NA
inhibitors according to a previous report [32]. Briefly, A/New
Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/
Mie/1/93 were incubated with approximately 10–20 IC90 of R-
125489, peramivir, zanamivir, or oseltamivir carboxylate at 37uC
for 60–90 min. Unbound NA inhibitors were removed from the
drug-virus mixtures with a Bio-Spin P-6 column (Bio-Rad
Laboratories, Hercules, CA). Using 0.1 mM MUNANA (Nacalai
Tesque, Inc., Kyoto, Japan) in 32.5 mM MES - 4 mM CaCl2
(pH 6.5) as a fluorescent substrate, we monitored the NA activity
of the drug-bound viruses every 15 min for 6 h at room
temperature by measuring the fluorescence at an excitation
wavelength of 360 nm and an emission wavelength of 460 nm.
Statistical analysis
Survival rates and median survival times of infected mice were
calculated by the Kaplan-Meier method [33]. A log-rank test
based on a joint ranking method was used to compare the
compound groups with the saline group. The analyses were
performed using the SAS System Release 8.2 for Windows (SAS
Institute, Inc., Cary, NC). P values less than 0.05 were considered
to be statistically significant.
Ethics
Our research protocol with mice followed the Regulations for
Animal Care and Use of the University of Tokyo and was
approved by the Animal Experiment Committee of the Institute
of Medical Science, the University of Tokyo (approval number:
19–29).
Results
Inhibitory effect of CS-8958 on the NA activity of H5N1
influenza viruses
To evaluate the efficacy of CS-8958 against H5N1 influenza
viruses, NA activity in the presence of various NA inhibitors was
measured in vitro (Table 1). The NA activity of the oseltamivir-
sensitive H5N1 influenza virus A/Hanoi/30408/05 clone7
(HN30408cl7) was inhibited by R-125489 (the active form of
CS-8958), oseltamivir carboxylate (the active form of oseltamivir),
and zanamivir, whereas that of the oseltamivir-resistant variants
HN30408 clone9 and clone3, which possess a histidine-to-tyrosine
substitution at position 274 (H274Y) and an asparagine-to-serine
substitution at position 294 (N294S) in NA, respectively [20], was
reduced by R-125489 and zanamivir, but not by oseltamivir
carboxylate. Similarly, wild-type A/Vietnam/1203/04 (H5N1;
VN1203) and its oseltamivir-resistant mutants were sensitive to R-
125489 and zanamivir at similar levels, whereas the sensitivity of
VN1203-H274Y and VN1203-N294S to oseltamivir carboxylate
was appreciably lower than that of the parent VN1203. Further,
the NA activity of A/Indonesia/UT3006/05 (H5N1; Ind3006), a
clade 2.1.3 virus, was also inhibited by oseltamivir carboxylate,
zanamivir and R-125489. These results indicate that R-125489
and zanamivir effectively inhibit the NA activity of H5N1 viruses,
including oseltamivir-resistant viruses and those of different clades.
Therapeutic efficacy of CS-8958 against H5N1 influenza
viruses in mice
To evaluate the therapeutic efficacy of CS-8958 against H5N1
influenza viruses, we used a murine lethal infection model. Two
Table 1. Inhibitory effect of R-125489, zanamivir, and oseltamivir carboxylate on the NA activity of H5N1 influenza viruses.
IC50 (95% confidential interval)
HN30408 VN1203 Ind3006
clone7 clone9 (H274Y
c) clone3 (N294S
c) Wild-type H274Y N294S
R-125489
a 0.32
d (0.18–0.56) 1.1 (0.84–1.3) 1.6 (0.84–2.4) 0.28 (0.27–0.29) 2.1 (1.4–3.0) 1.4 (0.48–2.6) 0.29 (0.24–0.35)
Zanamivir 0.72 (0.50–1.2) 0.68 (0.58–0.80) 0.57 (0.54–0.61) 0.15 (0.12–0.17) 0.22 (0.21–0.22) 0.48 (0.34–0.73) 0.070 (0.067–0.074)
Oseltamivir
carboxylate
b
0.35 (0.31–0.39) 430 (370–500) 1.6 (0.84–2.4) 0.31 (0.26–0.37) 1100 (570–1700) 28 (21–38) 10 (7.7–13)
aR-125489 is the active form of CS-8958.
bOseltamivir carboxylate is the active form of oseltamivir.
cThe H274Y and N294S mutations in NA confer oseltamivir-resistance to H5N1 influenza viruses [20].
dIC50 values: mean nmol/l of duplicate reactions.
doi:10.1371/journal.ppat.1000786.t001
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Ind3006, mice were given a single dose of CS-8958 intranasally
or oseltamivir phosphate orally as either a single dose or twice
daily for 5 days. Survival of infected mice was monitored daily for
21 days (Figure 1A and B). All the control mice died by 11 days pi.
The single dose of oseltamivir phosphate protected less than half of
the mice from lethal infection. However, the administration of
50 mg/kg of oseltamivir phosphate twice daily for 5 days saved
90% or 50% of mice infected with HN30408cl7 or Ind3006,
respectively. Under these conditions, the single 1,500 mg/kg dose
of CS-8958 protected 90% or 70% of mice from HN30408cl7 or
Ind3006, respectively.
To further evaluate the therapeutic efficacy of CS-8958 against
H5N1 viruses, we determined virus titers in lungs and brain of
HN30408cl7- or Ind3006-infected mice on days 3, 6, and 9 pi
(Table 2). CS-8958, at 750 or 1,500 mg/kg, dramatically inhibited
the replication of both viruses, particularly in the brain.
Interestingly, the efficacy of oseltamivir against Ind3006, which
is oseltamivir-sensitive, was limited with respect to reducing virus
titers in mouse organs, although its in vivo efficacy was evident
(Figure 1B). These results indicate that CS-8958 confers more
potent and long-lasting protection to mice against H5N1 influenza
viruses than does oseltamivir phosphate.
Therapeutic efficacy of CS-8958 against oseltamivir-
resistant H5N1 influenza viruses in mice
To evaluate the therapeutic efficacy of CS-8958 against
oseltamivir-resistant H5N1 influenza viruses, we used the
oseltamivir-resistant H5N1 viruses VN1203-H274Y and
VN1203-N294S. These mutant viruses (VN1203-H274Y and
VN1203-N294S) are as virulent as their parental virus, as shown
by their MLD50s: wild-type VN1203, 4.7 plaque-forming units
(PFU); VN1203-H274Y, 2.1 PFU; and VN1203-N294S, 4.7 PFU.
A single dose of CS-8958 was efficacious for mice infected with 4
Figure 1. Therapeutic efficacy of CS-8958 and oseltamivir phosphate against H5N1 influenza viruses in mice. Ten mice per group were
intranasally infected with 4 MLD50 of HN30408cl7 (A) or Ind3006 (B). The infected mice were given CS-8958 intranasally or oseltamivir phosphate
orally at the indicated doses 2 h post-infection (pi) or twice daily for 5 days beginning 2 h pi. Control mice received saline and water 2 h pi. Survival
was monitored daily for 21 days. P values were calculated by a log-rank test using a joint ranking method. Asterisk, P,0.05.
doi:10.1371/journal.ppat.1000786.g001
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type VN1203 (Figure 2). Oseltamivir phosphate, however, was less
effective against these two mutant viruses, as expected. Our data
thus demonstrate the therapeutic efficacy of CS-8958 against
oseltamivir-resistant H5N1 influenza viruses in mice.
Prophylactic efficacy of CS-8958 against H5N1 influenza
viruses in mice
To evaluate the prophylactic efficacy of CS-8958 against
H5N1 influenza viruses, we administrated HN30408cl7-infected
mice with CS-8958 intranasally or oseltamivir phosphate orally 7,
3, or 1 day before or 2 h after virus infection. The single CS-8958
dose of 750 or 1,500 mg/kg significantly protected mice from the
lethal infection even in mice who received the drug 7 days prior
to infection (p=0.0029and,0.0001, respectively). The prophy-
lactic efficacy of 75 mg/kg of CS-8958 and that of 10 or 100 mg/
kg of oseltamivir phosphate was, however, limited (Figures 3A
to D).
To further evaluate the prophylactic efficacy of CS-8958 against
H5N1 viruses, we determined the virus titers in the lungs and
brain of the infected mice on days 3, and 6 pi (Table 3). Compared
to oseltamivir-treated mice, those treated with 750 or 1,500 mg/kg
of CS-8958 exhibited lower levels of virus in the brain. In the lungs
on day 3 pi, virus titers were at least one log lower in animals
treated with 750 or 1,500 mg/kg of CS-8958 compared to those
treated with oseltamivir, although virus titers in the lungs on day 6
were only somewhat lower (less than one log in some cases) in mice
treated with 750 or 1,500 mg/kg of CS-8958 compared to
oseltamivir-treated mice. These results suggest that CS-8958
may be useful as both a therapeutic and a prophylactic drug
against H5N1 influenza viruses.
Binding stability of R-125489 to viruses
Bantia et al. [32] demonstrated that peramivir, a selective NA
inhibitor [28,34,35], binds to NA more tightly than oseltamivir
carboxylate or zanamivir by treating purified N9 NA with excess
(100 nM) NA inhibitors, removing the unbound NA inhibitors
and then measuring the NA activity over time. To assess the
binding stability of R-125489 to virus NA, we performed similar
experiments with the whole influenza virions A/New Caledonia/
20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/Mie/1/93
instead of purified NA; the NA activity of these viruses
treated with excess R-125489, peramivir, zanamivir, or oselta-
mivir carboxylate was measured (Figure 4 and Tables S1 and
S2).
We found a considerable difference in the dissociation rates of
the NA inhibitors among our test virus strains. For example, the
NA activity of A/Panama/2007/99 (H3N2) was severely inhibited
by all test NA inhibitors for at least 5 h, whereas the NA activity of
B/Mie/1/93 treated with oseltamivir carboxylate was almost fully
recovered by 3 h after substrate addition. Under these conditions,
R-125489 appreciably inhibited the NA activity of A/New
Caledonia/20/99 (H1N1) and A/Panama/2007/99 (H3N2) at a
level similar to that of peramivir. Further, it inhibited the NA
activity of B/Mie/1/93 by about 50%, even 6 h after substrate
addition, whereas no inhibitory effect was observed at this time
point for the other three NA inhibitors. These results suggest that
R-125489 bound to viral NA more stably than did any other NA
inhibitor tested.
Discussion
This is the first study to demonstrate that CS-8958 is effective
against H5N1 influenza viruses, including oseltamivir-resistant
Table 2. Virus titers in H5N1 virus-infected mice subsequently treated with drug.
Virus Treatment Virus titers (mean log10 PFU6SD/g) in:
Day 3 Day 6 Day 9
Lungs Brain Lungs Brain Lungs Brain
HN30408cl7 Control 5.960.4 ,1.6 5.861.1 4.6, 4.7 ND
a ND
CS-8958 75 mg/kg 4.1, 5.0 ,1.6 5.160.3 2.060.3 5.961.1 5.560.4
750 mg/kg 4.1, 4.5 ,1.6 4.0, 4.3 ,1.6 2.761.5 ,1.6
1,500 mg/kg 2.0 ,1.6 ,1.7 ,1.6 3.0, 3.5 ,1.6
Oseltamivir phosphate 10 mg/kg 6.260.2 ,1.6 6.460.6 4.861.5 6.1 5.1
100 mg/kg 6.060.1 ,1.6 5.260.1 2.5, 2.5 4.961.8 4.8
5 mg/kg twice daily for 5 days 5.060.6 ,1.6 5.560.4 2.960.4 4.760.6 4.760.4
50 mg/kg twice daily for 5 days 5.0, 5.3 ,1.6 3.860.5 ,1.6 4.761.4 3.7
Ind3006 Control 7.260.1 ,1.6 7.360.2 3.760.3 ND ND
CS-8958 75 mg/kg 6.460.2 ,1.6 7.260.1 ,1.6 ,1.7 ,1.6
750 mg/kg 6.0, 6.0 ,1.6 6.0, 6.9 ,1.6 ,1.7 ,1.6
1,500 mg/kg 2.4, 4.8 ,1.6 4.561.4 ,1.6 ,1.7 ,1.6
Oseltamivir phosphate 10 mg/kg 7.560.1 ,1.6 7.560.2 3.160.3 ,1.7 ,1.6
100 mg/kg 7.260.1 ,1.6 7.460.2 2.660.1 ,1.7 ,1.6
5 mg/kg twice daily for 5 days 6.5, 7.2 ,1.6 7.460.1 3.261.2 ,1.7 ,1.6
50 mg/kg twice daily for 5 days 7.160.2 ,1.6 7.260.1 3.360.9 ,1.7 ,1.6
Three mice per group were intranasally infected with 4 MLD50 of HN30408cl7 or Ind3006 and given CS-8958 intranasally or oseltamivir phosphate orally at the indicated
doses 2 h post-infection (pi) or twice daily for 5 days beginning 2 h pi, respectively. Control mice received saline and water 2 h pi. When only one or two mice in a
group were negative for virus, individual titers were recorded.
aND: no data since all mice died by day 9.
doi:10.1371/journal.ppat.1000786.t002
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Eight mice per group were intranasally infected with 4 MLD50 of wild-type VN1203 (A), VN1203-H274Y (B), or VN1203-N294S (C). The infected mice
were given CS-8958 intranasally or oseltamivir phosphate orally at the indicated doses 2 h post-infection (pi) or twice daily for 5 days beginning 2 h
pi. Control mice received saline and water 2 h pi. Survival was monitored daily for 21 days. P values were calculated by a log-rank test using a joint
ranking method. Asterisk, P,0.05.
doi:10.1371/journal.ppat.1000786.g002
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PLoS Pathogens | www.plospathogens.org 6 February 2010 | Volume 6 | Issue 2 | e1000786Figure 3. Prophylactic effect of CS-8958 and oseltamivir phosphate against H5N1 influenza viruses in mice. Eight mice per group were
given CS-8958 intranasally or oseltamivir phosphate orally at the indicated doses on day 7 (A), 3 (B) or 1 (C) before or 2 h (D) after infection with 4
MLD50 of HN30408cl7. Control mice received saline and water 2 h post-infection. Survival was monitored daily for 21 days. P values were calculated
by a log-rank test using a joint ranking method. Asterisk, P,0.05.
doi:10.1371/journal.ppat.1000786.g003
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binding of R-125489 to NA. Previous animal studies suggest that
increased or extended doses of oseltamivir phosphate are needed
to protect mice and ferrets against recent H5N1 strains, which are
more virulent than their predecessors [36]. Moreover, recent
Indonesian clade 2 H5N1 isolates have reduced sensitivity to
oseltamivir [37]. Here, we showed that CS-8958 inhibits the NA
activity of oseltamivir-sensitive and -resistant H5N1 viruses in vitro
(Table 1). In mice, CS-8958 exhibited a strong and lasting
therapeutic effect against both oseltamivir-sensitive and -resistant
H5N1 viruses (Figures 1 and 2). These results clearly indicate that
CS-8958 is effective even against H5N1 virus strains to which the
efficacy of oseltamivir phosphate is limited.
To further evaluate the therapeutic efficacy of CS-8958 against
H5N1 viruses, we determined virus titers in lungs and brain of
HN30408cl7- or Ind3006-infected mice on days 3, 6, and 9 pi
(Table 2). CS-8958, at 750 or 1,500 mg/kg, dramatically inhibited
the replication of both viruses, particularly in the brain. These
results indicate that CS-8958 confers more potent and long-lasting
protection to mice against H5N1 influenza viruses than does
oseltamivir phosphate.
We also observed a prophylactic effect of CS-8958 against
H5N1 viruses in mice (Figure 3). Similar efficacy was demonstrat-
ed in mice infected with a mouse-adapted A/Puerto Rico/8/34
[21]. Although studies in higher mammals (e.g., ferrets and
macaques) are required, this noteworthy feature of CS-8958 may
prove to be an important differentiator with respect to other NA
inhibitors (i.e., oseltamivir phosphate, zanamivir, and peramivir).
The long-lasting therapeutic and prophylactic efficacy of
intranasally-administrated CS-8958 in mice was previously
thought to be due to its rapid metabolism to R-125489 and the
retention of the metabolite in the lungs [21] (Koyama et al.,
unpublished data). However, peramivir, which exhibits significant
therapeutic efficacy in mice following a single intramuscular
injection, was shown to bind to N9 NA more tightly than
oseltamivir carboxylate or zanamivir [32]. Here, we revealed that
the binding stabilities of R-125489 to H1N1 and H3N2 viruses are
comparable to that of peramivir and are superior to that of
peramivir for type B virus (Figure 4). These findings suggest that
the tight binding to NA may also account for the long-lasting
therapeutic and prophylactic effects of CS-8958 in vivo.
Importantly, a single dose of CS-8958 conferred a more potent
and long-lasting protective effect to mice against H5N1 influenza
viruses than that of oseltamivir phosphate. CS-8958 is, therefore, a
promising candidate for a new neuraminidase inhibitor to prevent
and treat influenza patients infected with H5N1 and other subtype
viruses.
Supporting Information
Table S1 Slopes of the dissociation curve
a.
aSlopes of the
dissociation curve for each compound were estimated based upon
the fluorescence from 0 to 50000 by a linear regression analysis
assuming the intercepts equal to 0.
Found at: doi:10.1371/journal.ppat.1000786.s001 (0.04 MB
DOC)
Table S2 Statistical analysis of slopes
a.
aThe slope difference and
the 95% confidential interval (CI) between the slopes of two
compound were compared and the corresponding P values were
calculated.
bThe numbers represent each compound as follows; 1:
R-125489, 2: Zanamivir, 3: Oseltamivir carboxylate, 4: Peramivir,
5: Background.
Found at: doi:10.1371/journal.ppat.1000786.s002 (0.05 MB
DOC)
Table 3. Prophylactic efficacy of CS-8958 as measured by H5N1 virus growth in mice.
Drug given at: Treatment Virus titer (mean log10 PFU6SD/g) in:
Day 3 Day 6
Lungs Brain Lungs Brain
+2 h Control 6.060.2 ,1.6 6.661.0 4.661.1
27 days CS-8958 75mg/kg 5.660.3 ,1.6 6.760.3 1.961.7
750mg/kg 4.560.6 ,1.6 6.360.2 4.0
1500mg/kg 4.560.3 ,1.6 5.060.4 ,1.6
Oseltamivir phosphate 100mg/kg 5.860.8 ,1.6 6.060.4 1.6, 2.4
23 days CS-8958 75mg/kg 5.460.2 ,1.6 6.260.2 ,1.6
750mg/kg 4.760.3 ,1.6 4.860.1 ,1.6
1500mg/kg 4.160.6 ,1.6 4.161.3 ,1.6
Oseltamivir phosphate 100mg/kg 5.560.7 ,1.6 5.660.4 2.4, 2.8
21 day CS-8958 75mg/kg 3.262.8 ,1.6 5.660.4 ,1.6
750mg/kg 3.560.8 ,1.6 4.761.0 ,1.6
1500mg/kg 2.960.3 ,1.6 4.761.2 ,1.6
Oseltamivir phosphate 100mg/kg 4.361.9 ,1.6 6.160.2 2.6
+2 h CS-8958 75mg/kg 5.160.2 ,1.6 5.860.6 ,1.6
750mg/kg 3.960.6 ,1.6 5.561.5 ,1.6
1500mg/kg 1.462.5 ,1.6 3.660.8 ,1.6
Oseltamivir phosphate 100mg/kg 3.262.9 ,1.6 6.060.0 ,1.6
Three mice per group were intranasally infected with 4 MLD50 of HN30408cl7 and given CS-8958 intranasally or oseltamivir phosphate orally at the indicated doses at
the indicated time points. Control mice received saline and water. When only one or two mice in a group were negative for virus, individual titers were recorded.
doi:10.1371/journal.ppat.1000786.t003
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PLoS Pathogens | www.plospathogens.org 8 February 2010 | Volume 6 | Issue 2 | e1000786Figure 4. Binding stability of NA inhibitors to viruses. The NA activity of A/New Caledonia/20/99 (H1N1; A), A/Panama/2007/99 (H3N2; B), and
B/Mie/1/93 (C) untreated [NA inhibitor (-)] or treated with excess R-125489, peramivir, zanamivir, or oseltamivir carboxylate, was monitored every
15 min for 6 h.
doi:10.1371/journal.ppat.1000786.g004
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